

BEST AVAILABLE COPY



Bib Data Sheet

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

<b>SERIAL NUMBER</b> 09/505,788	<b>FILING DATE</b> 02/17/2000 <b>RULE</b> -	<b>CLASS</b> 514	<b>GROUP ART UNIT</b> 1614	<b>ATTORNEY DOCKET NO.</b> PH-7076-A
<b>APPLICANTS</b> Richard E. Olson, Wilmington, DE ;				
<b>** CONTINUING DATA *****</b> THIS APPLICATION IS A CIP OF 09/469,939 12/24/1999 WHICH CLAIMS BENEFIT OF 60/113,588 12/24/1998				
<b>** FOREIGN APPLICATIONS *****</b>				
<b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED</b> ** 05/09/2000				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Verified and <u>Brenda Coleman</u> Acknowledged <u>OC</u> Examiner's Signature Initials		<b>STATE OR COUNTRY</b> DE	<b>SHEETS DRAWING</b> -	<b>TOTAL CLAIMS</b> 24
				<b>INDEPENDENT CLAIMS</b> 3
<b>ADDRESS</b>  Scott K Larsen DuPont Pharmaceuticals Company c/o E I du Pont de Nemours and Co Legal Patents 1007 Market Street Wilmington, DE 19898				
<b>TITLE</b> Succinoylamino benzodiazepines as inhibitors of AB protein production				
<b>FILING FEE RECEIVED</b> 1260	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	